The identification of tumour infiltrating lymphocytes (TILs) and their role in treatment responses [12] as well as genomic evidence for immune responses in TNBC and HER2+ disease [13] renewed interest in this therapeutic strategy for these sub-types of breast cancer. The gene discussed is ERBB2; the disease is breast cancer.